SMSPHARMA

SMS Pharmaceuticals share price & financials

Price
₹378.6
Market cap
₹4.3k Cr
Sector
Healthcare
Calls analysed
3
Latest concall · Q4 FY26 · call held 27 May 2026

SMS Pharma. Q4 FY26

Revenue ₹238 cr EBITDA ₹40 cr EBITDA Margin 17% PAT ₹33 cr

What went well

  • FY26 revenue increased by 13% to ₹887 crores, driven by strong growth in anti-inflammatory and ARV segments.
  • FY26 EBITDA stood at ₹171 crores, up 23% YoY, with margins improving to 20% due to backward integration, favorable product mix, and operating leverage.
  • FY26 PAT rose 47% to ₹102 crores, supported by margin expansion and a ₹14 crores contribution from VKT Pharma.

What to watch

  • QoQ gross profit margin declined by 2% in Q4 FY26 due to increased raw material consumption and a drastic increase in solvent costs, primarily attributed to geopolitical events.
  • Geopolitical developments in the Middle East have introduced uncertainties around logistics, freight movements, and supply chain stability for raw materials and finished products, leading to a conservative FY27 revenue growth guidance of 15%.
Read the full call →

What SMS Pharmaceuticals Limited does

SMS Pharmaceuticals is a vertically integrated manufacturer of Active Pharmaceutical Ingredients (APIs), operating two globally-accredited plants at Hyderabad and Vizag (Telangana, Andhra Pradesh). It develops and supplies APIs across therapeutic areas including anti-retrovirals, anti-inflammatories, anti-diabetics, anti-migraine, anti-ulcer, anti-erectile-dysfunction and anti-epileptic drugs, selling into more than 75 countries including regulated markets such as Europe and North America. The company backward-integrates key raw materials (e.g. for ibuprofen) to reduce import dependency and protect margins, and holds a stake in associate company VKT Pharma for forward integration. An in-house R&D team files DMFs/CEPs and process patents to build a pipeline of new APIs and high-value molecules, including an emerging peptides and CDMO initiative.

Segments

  • Anti Retro Viral (ARV)
  • Anti-inflammatory
  • Anti-diabetic
  • Anti-migraine
  • Anti-erectile dysfunction
  • Anti-epileptic
  • Anti-ulcer
  • Anti-anginal
  • Others
Manufacturing facilities
2 (Hyderabad and Vizag, Telangana/Andhra Pradesh)
Total reactor volume
3,120 KL (Hyderabad 120 KL + Vizag 3,000 KL)
APIs manufactured
55+ across 14 therapeutic segments
DMFs filed to date
120+
Employees
1,600+
R&D scientists
100+
Founded 1987Headquarters Hyderabad, Telangana, India Company website

Guidance record · Q4 FY26

what the last two calls moved 11 tracked 2 delivered 2 missed 7 open
  • EBITDA Margin delivered said Q4 FY25 Promised: Aiming to expand our EBITDA margins by 20% (to 20%) Q4 FY26: FY26 EBITDA stood at ₹171 crores, up 23% YoY, with margins improving to 20%.
  • Revenue Growth missed said Q4 FY25 Promised: Targeting 20% revenue growth for FY26 Q4 FY26: FY26 revenue increased by 13% to ₹887 crores.
  • Capex Plan delayed said Q4 FY25 Promised: INR250 crores over the next 18 months Q4 FY26: The INR280 crores capex will be completed by FY27, March. INR130 crores has been invested so far.

All 11 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 5.6%, net profit up 5.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue197 173 248 196 242 +23%210 +21%238 −4%207 +6%
EBITDA31 33 41 39 48 +55%44 +33%40 −2%41 +5%
Net profit14 18 20 20 25 +79%23 +28%33 +65%21 +5%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +72.9% 1Y

₹250₹300₹350₹400₹450Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 11 Nov 2025Q4 FY26 — 27 May 2026

1Y: ₹268.03 on 10 Sept 2025 → ₹463.45. High ₹463.45 (11 Sept 2026), low ₹244.3 (29 Sept 2025).

How the price took the results

close before → close after

Q4 FY26
+0.3%
27 May
Q2 FY26
−0.6%
11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 19.4% a year over 3 years, FY23 to FY26. Operating margin widened to 19.3%.

Year endingFY23FY24FY25FY26
Revenue₹521 Cr₹709 Cr₹782 Cr₹886 Cr
Operating profit₹55 Cr₹117 Cr₹139 Cr₹171 Cr
Operating margin10.6%16.5%17.8%19.3%
Interest₹22 Cr₹24 Cr₹19 Cr₹23 Cr
Depreciation₹32 Cr₹32 Cr₹35 Cr₹40 Cr
Net profit₹2 Cr₹49 Cr₹68 Cr₹101 Cr
Net margin0.4%6.9%8.7%11.4%
Cash from operations₹22 Cr₹50 Cr₹82 Cr₹59 Cr
Free cash flow₹-7 Cr₹-2 Cr₹-42 Cr₹-71 Cr
ROCE4.0%12.0%13.0%13.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹8 Cr₹8 Cr₹8 Cr₹8 Cr₹9 Cr₹9 Cr
Reserves₹402 Cr₹462 Cr₹452 Cr₹528 Cr₹751 Cr₹776 Cr
Borrowings₹255 Cr₹263 Cr₹254 Cr₹281 Cr₹324 Cr₹365 Cr
Other liabilities₹147 Cr₹126 Cr₹165 Cr₹217 Cr₹221 Cr₹212 Cr
Total liabilities₹812 Cr₹860 Cr₹880 Cr₹1.0k Cr₹1.3k Cr₹1.4k Cr
Fixed assets₹457 Cr₹438 Cr₹412 Cr₹437 Cr₹517 Cr₹534 Cr
Capital work in progress₹7 Cr₹11 Cr₹33 Cr₹30 Cr₹50 Cr₹122 Cr
Investments₹27 Cr₹22 Cr₹11 Cr₹11 Cr₹48 Cr₹26 Cr
Other assets₹321 Cr₹389 Cr₹424 Cr₹556 Cr₹690 Cr₹681 Cr
Total assets₹812 Cr₹860 Cr₹880 Cr₹1.0k Cr₹1.3k Cr₹1.4k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −2.23 pp while promoters added +1.80 pp. The shareholder count shrank 6% to 31,489.

Promoters
68.1%
FIIs
0.7%
DIIs
2.8%
Public
28.4%

Since Jun 2025

  • Public −2.23 pp
  • Promoters +1.80 pp
  • FIIs +0.62 pp

How it drifted, 12 quarters

Over this window the public fell from 35.1% to 28.4% — −6.6 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 64.3%, FIIs 0.6%, Public 35.1%.Dec '23: Promoters 64.3%, FIIs 0.6%, Public 35.1%.Mar '24: Promoters 64.7%, FIIs 0.2%, DIIs 2.0%, Public 33.2%.Jun '24: Promoters 64.7%, FIIs 0.2%, DIIs 2.1%, Public 33.0%.Sep '24: Promoters 64.7%, FIIs 0.5%, DIIs 2.5%, Public 32.3%.Dec '24: Promoters 64.7%, FIIs 0.3%, DIIs 2.5%, Public 32.5%.Mar '25: Promoters 66.3%, FIIs 0.1%, DIIs 2.4%, Public 31.2%.Jun '25: Promoters 66.3%, FIIs 0.0%, DIIs 3.0%, Public 30.7%.Sep '25: Promoters 68.1%, FIIs 0.3%, DIIs 2.9%, Public 28.8%.Dec '25: Promoters 68.1%, FIIs 0.0%, DIIs 3.2%, Public 28.7%.Mar '26: Promoters 68.1%, FIIs 0.3%, DIIs 3.0%, Public 28.6%.Jun '26: Promoters 68.1%, FIIs 0.7%, DIIs 2.8%, Public 28.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of SMS Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Ramesh Babu Potluri 19.38%unchanged
Vamsi Krishna Potluri 16.90%unchanged
Hima Bindu Potluri 16.03%unchanged
Potluri Infra Projects Llp 9.45%unchanged
Trilok Potluri 5.01%unchanged
Quant Mutual Fund - Quant Small Cap Fund Mutual fund2.81%−0.15 pp
Aniruddh Mundra 2.01%newly disclosed
Venkata Subbaraju Penmatsa HUF 1.82%unchanged
Sudeepthi Gopineedi 1.41%unchanged
Venkata Praveen Talluri 1.41%unchanged
Potluri Laboratories Private Limited 1.20%unchanged
Tvt Infracon Llp 0.11%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Attractive

To justify its price of ₹463, this stock must grow earnings at 27% every year for 7 years. Our analysis caps realistic growth at ~250%. At that growth it is worth ₹443387 — upside of 95571%.

Growth the price implies
27.2% a year
for 7 years, fading to 4%
It has actually compounded at
265.9% a year
net profit, FY23–FY26 · EPS 249.6%
The gap
-2.2 pp
95571% downside if it only repeats history
Price today ₹463.45 Value at the reference growth ₹4,43,386.77

Change the assumptions yourself →

All earnings calls (3)

Read the Q4 FY26 call →

Learn to analyse SMS Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.